Angiotensin III-induced modulation of neurogenic responses in the rabbit vas deferens and portal vein.
The effects of prostaglandin synthesis inhibitors on the presynaptic actions of angiotensin (ang) II and III were examined in isolated rabbit vasa deferentia and portal veins. Ang II caused dose-dependent potentiation of low frequency, nerve stimulation in vasa deferentia and portal vein. Indomethacin (26 microM) enhanced the electrically-induced contractions in the vasa deferentia only but did not alter the potency of ang II in either preparation. In contrast, ang III decreased contractions in vasa deferentia induced by nerve stimulation by up to 36% (10(-6) M) and potentiated these contractions at concentrations higher than 10(-6) M. The inhibitory action of ang III on vasa deferentia was converted to potentiation by pretreatment with indomethacin or mepacrine. Exogenous PGE2 blocked low frequency nerve stimulation and not responses to norepinephrine. This prostaglandin appeared to mimic ang III in the vas deferens. No effects of ang III were observed if the contractions were induced by exogenous alpha adrenergic agonists. [Sar1, Ala8] ang II antagonized all responses to the angiotensins, whereas [Sar1, Cys-CH3(8)] ang II selectively antagonized the angiotensin-induced potentiation. Responses in field-stimulated portal veins were potentiated by ang III and this response was unaffected by indomethacin. This investigation strongly suggests the existence of at least two ang receptors in the vas deferens and demonstrates for the first time selective responses to the octa- and heptapeptides in the same effector organ.
D000804:Angiotensin II / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000494:pharmacology; D000805:Angiotensin III / Q000494:pharmacology*; D000818:Animals; D016861:Cyclooxygenase Inhibitors; D015232:Dinoprostone; D004558:Electric Stimulation; D066298:In Vitro Techniques; D007213:Indomethacin / Q000494:pharmacology; D008297:Male; D008469:Meclofenamic Acid / Q000494:pharmacology; D009130:Muscle, Smooth / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D009638:Norepinephrine / Q000494:pharmacology; D010656:Phenylephrine / Q000494:pharmacology; D010740:Phospholipases / Q000037:antagonists & inhibitors; D011169:Portal Vein / Q000187:drug effects / Q000294:innervation / Q000502:physiology*; D011458:Prostaglandins E / Q000494:pharmacology; D011796:Quinacrine / Q000494:pharmacology; D011817:Rabbits; D017981:Receptors, Neurotransmitter / Q000187:drug effects; D013564:Sympathetic Nervous System / Q000187:drug effects; D014649:Vas Deferens / Q000187:drug effects / Q000294:innervation / Q000502:physiology*
D016861:Cyclooxygenase Inhibitors; D011458:Prostaglandins E; D017981:Receptors, Neurotransmitter; D000804:Angiotensin II; D000805:Angiotensin III; D010656:Phenylephrine; D008469:Meclofenamic Acid; D010740:Phospholipases; D011796:Quinacrine; D015232:Dinoprostone; D009638:Norepinephrine; D007213:Indomethacin